The ESCEO algorithm - said Prof Jean-Yves Reginster, ESCEO co-founder and President - recommends the use of SYSADOAs specifically patented crystalline glucosamine sulfate and prescription chondroitin sulfate as a first line treatment for OA; it is clear today that not all the products are similar, and the discrepancies between various guidelines simply reflect the fact that they do not consider the same medications.
Our first take home message from the meeting on which we are all agreed, is that glucosamine hydrochloride is just a placebo.
Regarding glucosamine sulfate there are differences between the preparations available today - added Prof Reginster.
An important step towards harmonization of different treatment modalities has been done in this consensus meeting: the task force agreed on differentiating between the clinically proven, prescription-only formulation of patented crystalline glucosamine sulfate and other preparations of glucosamine.
Based on clinical evidences, patented crystalline glucosamine sulfate: